Skip to content
2000
Volume 24, Issue 1
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Over the centuries, influenza and its associated epidemics have been a serious public health problem. Although vaccination and medications (such as neuraminidase inhibitors) are the mainstay of pharmacological approaches to prevent and treat influenza, however, frequent mutations in the influenza genome often result in treatment failure and resistance to standard medications which limit their effectiveness. In recent years, green tea catechins have been evaluated as potential anti-influenza agents. Herein, in this review, we highlighted the effects and mechanisms underlying the inhibitory effects of epigallocatechin 3-gallate (EGCG), the most abundant ingredient in green tea, against different influenza viral infections, and their clinical benefits toward prevention and treatment. In addition, as the severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) causes the outbreak of COVID-19 pandemic, our review also delineates the current perspective on SARS-CoV-2 and future insights as to the potential application of EGCG on suppressing the flu-like symptoms caused by COVID-19.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/0115680266251803230925075508
2024-01-01
2025-06-21
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/0115680266251803230925075508
Loading

  • Article Type:
    Review Article
Keyword(s): Anti-viral; COVID-19; EGCG; Green tea; Influenza; Natural product
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test